Article Text

Download PDFPDF
Review: lack of evidence for the optimal dose of risperidone for schizophrenia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.



What is the most effective dose of risperidone for treating schizophrenia and schizophrenia-like psychoses?


Primary: no clinically important change in short-term global state. Outcomes were classified as short (up to 12 weeks), medium (13–26 weeks) and long term (>26 weeks). Secondary: early study withdrawal for any reason, global state, relapse, need for additional medication, mental state, symptom scores, general functioning, social or life skill functioning, behaviour, quality of life, satisfaction with treatment, cognitive functioning, service use, adverse events and costs of treatment.



Systematic review and meta-analysis.

Data sources:

The Cochrane Schizophrenia Group Trials Register was searched in July 2008. Reference lists of included and excluded studies and the FDA website were also searched, and a pharmaceutical company was also contacted to locate any additional studies.

Study selection and analysis:

Two reviewers independently selected potentially relevant studies. Inclusion criteria were randomised controlled trials (including quasi-randomised and crossover designs) evaluating risperidone in any oral form or dose in people with schizophrenia or other types of schizophrenia-like disorders. Doses were categorised as low (2 to <4 mg/day), standard-lower (4 to <6 mg/day), standard-high (6 to <10 mg/day) and high (≥10 mg/day). Psychometric outcomes were only …

View Full Text


  • Source of funding None stated.


  • Competing interests ML has received reimbursements, fees and funds from JanssenCilag, Eli Lilly, BristolMyers Squibb, AstraZeneca and Pfizer.

Linked Articles